OneAscent Wealth Management LLC Increases Holdings in Bristol-Myers Squibb (NYSE:BMY)

OneAscent Wealth Management LLC grew its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 5.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 5,992 shares of the biopharmaceutical company’s stock after acquiring an additional 288 shares during the period. OneAscent Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $325,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in BMY. Northwest Financial Advisors purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $27,000. Pacific Capital Wealth Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $34,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $40,000. Wetzel Investment Advisors Inc. purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $40,000. Finally, Fairman Group LLC purchased a new position in shares of Bristol-Myers Squibb during the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

NYSE BMY opened at $41.53 on Friday. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The stock has a market capitalization of $84.19 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.20 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.38. The business’s fifty day moving average price is $42.97 and its 200-day moving average price is $48.14.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. Bristol-Myers Squibb’s revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business posted $2.05 EPS. On average, equities analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be paid a $0.60 dividend. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Barclays dropped their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Finally, StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.